Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

FEMY vs RNAZ: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

RNAZ Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 5–2 Matrix Metrics)

RNAZ Overall Winner 6-Pillar Tally: FEMY 2 – 2 RNAZ (2 Tie) Matrix Metrics: FEMY 2 – 5 RNAZ

As of Nov 16, 2026, TransCode Therapeutics, Inc. (RNAZ) is the stronger overall head-to-head candidate over Femasys Inc. (FEMY) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). FEMY carries a Unified Composite Score of 52.6/100 (HOLD) at $1.28 (N/M Forward P/E, -763.9% operating margin), whereas RNAZ carries 50.3/100 (HOLD) at $1.35 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While FEMY currently prints a higher short-term Unified Composite Score (52.6/100 HOLD vs. RNAZ 50.3/100 HOLD), RNAZ captures the overall institutional head-to-head verdict (5–2 matrix metrics and 2–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -763.9% operating margin) and revenue trajectory (+0.0% vs. -18.9% YoY).
  • Technical & Structure Timing Caution: FEMY is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.6); meanwhile RNAZ is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About FEMY vs RNAZ
FEMY NASDAQ
Femasys Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$1.28
-9.86% 1D
Market Cap $11.9M
TTM Revenue $2.3M
Forward P/E N/M
Beta / 30D Vol 4.01β · 72% Vol
Unified Composite Score
52.6 / 100 HOLD
Tech 61.0 Fund 62.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -21.5%), weak momentum, RSI 35
RSI-14: 34.6 · SMA20: $1.43 · SMA50: $1.92
RNAZ NASDAQ Head-to-Head Winner
TransCode Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$1.35
+2.27% 1D
Market Cap $22.3M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.96β · 63% Vol
Unified Composite Score
50.3 / 100 HOLD
Tech 53.0 Fund 48.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -22.4%), weak momentum, RSI 34
RSI-14: 34.1 · SMA20: $1.57 · SMA50: $1.65

6-Pillar Scorecard Institutional Category Breakdown (FEMY 2 – 2 RNAZ)

Columns: Metric · FEMY · RNAZ
1. Valuation Multiples FEMY
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 4.9x N/M
2. Growth & Scale RNAZ
Revenue Growth (YoY) -18.9% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $2.3M N/A
Market Cap $11.9M $22.3M
3. Profitability & Quality RNAZ
Gross Margin 60.9% N/A
Operating Margin -763.9% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -425.0% -59.3%
4. Balance Sheet & Cash Flow FEMY
Cash Generation (TTM) -$19M -$21M
Cash Flow Margin N/A N/A
Net Cash / Leverage -$658,045 Net Debt (0.65x D/E) -59.3% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Instruments & Supplies Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: FEMY (2) vs RNAZ (5)
Institutional Metric FEMY RNAZ Criterion Row Edge
Market Capitalization
Scale
$11.9M $22.3M Larger Scale RNAZ
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-18.9% +0.0% Higher Growth RNAZ
Operating Margin (TTM)
Profitability
-763.9% 0.0% Higher Margin RNAZ
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-425.0% -59.3% Higher ROE RNAZ
52-Week Range Position
Momentum
17% ($0–$6) 0% ($1–$13) Stronger Trend FEMY
Beta / 30D Volatility
Risk Regime
4.01β · 72% Vol 0.96β · 63% Vol Lower Realized Risk RNAZ
Unified Institutional Score
Composite Signal
52.6 / 100 (HOLD) 50.3 / 100 (HOLD) Higher Composite FEMY
Trailing 12M Revenue (USD)
Operating Scale
$2.3M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
60.9% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 4.9x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$19M (-$658,045 Net Debt (0.65x D/E)) -$21M (-59.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon RNAZ +1.83 pp
FEMY: -22.42% · RNAZ: -20.59%
3M Horizon FEMY +16.51 pp
FEMY: -41.82% · RNAZ: -58.33%
6M Horizon FEMY +338.5 pp
FEMY: +258.95% · RNAZ: -79.55%
1Y Horizon FEMY +138.75 pp
FEMY: +54.78% · RNAZ: -83.97%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on FEMY vs RNAZ. Trailing 12-month operating profitability (FEMY -763.9% vs RNAZ 0.0%) and valuation multiples (FEMY N/M vs RNAZ N/M Forward P/E) are benchmarked directly in Pillar 4 below.

FEMY ADR TTM Benchmark FX-Normalized USD
TTM Revenue$2.3M
Gross Margin60.9%
Op. Margin-763.9%
ROE / Fwd P/E-425.0% · N/M
RNAZ ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-59.3% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
FEMY UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact FEMY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
RNAZ UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact RNAZ Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
FEMY Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $11.9M market capitalization and -763.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
RNAZ Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $22.3M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ FEMY vs RNAZ Key Questions & Quantitative Answers

As of Nov 16, 2026, TransCode Therapeutics, Inc. (RNAZ) is the stronger overall head-to-head candidate over Femasys Inc. (FEMY) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). FEMY carries a Unified Composite Score of 52.6/100 (HOLD) at $1.28 (N/M Forward P/E, -763.9% operating margin), whereas RNAZ carries 50.3/100 (HOLD) at $1.35 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While FEMY currently prints a higher short-term Unified Composite Score (52.6/100 HOLD vs. RNAZ 50.3/100 HOLD), RNAZ captures the overall institutional head-to-head verdict (5–2 matrix metrics and 2–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -763.9% operating margin) and revenue trajectory (+0.0% vs. -18.9% YoY). Technical & Structure Timing Caution: FEMY is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.6); meanwhile RNAZ is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

RNAZ leads the Growth & Scale pillar: FEMY posts -18.9% YoY revenue growth and +0.0% YoY earnings growth on $2.3M TTM revenue (60.9% gross margin, -763.9% operating margin), compared with RNAZ at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, FEMY generates $2.3M in USD-normalized revenue versus N/A for RNAZ. In operating R&D and SG&A reinvestment, FEMY deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for RNAZ.

FEMY screens cheaper on headline valuation multiples. FEMY trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 4.9x EV/Revenue (unreported FCF margin), whereas RNAZ trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against FEMY (-425.0% ROE) versus RNAZ (-59.3% ROE) capital efficiency.

In options market volatility and institutional positioning, FEMY carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (4.01β · 72% Vol realized risk). By comparison, RNAZ carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.96β · 63% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.